ImmunityBio Reports Stellar Revenue Growth Fueled by Global Expansion

ImmunityBio's 2025 revenue soared 700% to $113M, fueled by ANKTIVA's global rollout and 750% sales volume growth, while net losses narrowed significantly.

ImmunityBio has announced a remarkable financial performance for its latest fiscal year, driven by the explosive commercial uptake of its immunotherapy drug, ANKTIVA®. The company's product revenue skyrocketed to $113 million, marking an increase of approximately 700% for 2025. This surge is attributed to a substantial rise in unit sales volume, which grew by 750% year-over-year, supported by a series of strategic regulatory approvals across key global markets.

Regulatory Milestones Pave the Way for International Reach

A cornerstone of the company's success is its rapid regulatory progress. In a significant development for European patients, the European Commission granted a conditional marketing authorization for ANKTIVA in February 2026. The approval covers its use in combination with Bacillus Calmette-Guérin (BCG) for a specific form of non-muscle invasive bladder cancer (NMIBC). This authorization makes the therapy available across all 27 European Union member states, as well as in Iceland, Norway, and Liechtenstein. To date, ANKTIVA has secured marketing approvals in a total of 33 countries.

The therapy's journey from its initial U.S. Food and Drug Administration (FDA) approval in April 2024 to its current status has been swift. Within less than two years, it has gained market access in four major regulatory territories: the United States, the United Kingdom, Saudi Arabia, and the European Union.

Strategic Partnerships Accelerate Commercial Rollout

To execute its aggressive international expansion, ImmunityBio has established key distribution alliances. For the European market, the company entered into an agreement with Accord Healthcare, leveraging a distribution network spanning 30 countries. In support of this European market entry, ImmunityBio has also established an Irish subsidiary based in Dublin.

Concurrently, the company has partnered with Biopharma and Cigalah Healthcare to introduce ANKTIVA in Saudi Arabia and the broader MENA region. The Saudi Food and Drug Authority (SFDA) approved the therapy through an accelerated procedure for both bladder cancer and metastatic non-small cell lung cancer.

Financial Performance: Soaring Sales and a Narrowing Loss

The fourth quarter of 2025 alone contributed $38.3 million in product revenue, underscoring the strong commercial momentum. Despite this period of intense growth, ImmunityBio continued to report a net loss. However, the loss showed significant improvement, contracting to $351.4 million compared to $413.6 million in the prior year.

The company's trajectory appears firmly set on growth. With unit sales volume multiplying, revenue climbing dramatically, and net losses shrinking, ImmunityBio's strategy is yielding tangible results. The broadening global availability of its flagship therapy provides a solid foundation for its ongoing commercial journey.